PROTIA Unveils Advanced Veterinary Diagnostic Technologies at WVC 2025

PROTIA, a leading developer of in-vitro diagnostic medical devices, is set to present innovative veterinary diagnostic technologies at the Western Veterinary Conference (WVC) in Las Vegas, highlighting groundbreaking solutions for animal health management.

The company will showcase three primary diagnostic products designed to revolutionize veterinary healthcare: the 'ANITIA Canine/Feline IgE' allergy diagnostic kit, the 'ANITIA Equine IgE' allergy diagnostic kit, and the 'AniCheck Bovine/Equine IgG' immunity measurement technology.

The ANITIA Canine/Feline IgE diagnostic kit represents a significant advancement in pet healthcare, enabling veterinarians to rapidly and accurately identify allergens in dogs and cats. This technology allows for swift development of targeted treatment strategies, potentially improving the quality of life for companion animals.

Launched in July 2024, the ANITIA Equine IgE diagnostic product utilizes a sophisticated Parallel Line Array (PLA) system capable of diagnosing 120 different allergens through equine serum. This technology provides horse owners and veterinarians with comprehensive insights into potential allergic reactions, facilitating proactive health management and performance optimization.

Another critical innovation is the AniCheck Bovine/Equine IgG technology, which addresses newborn animal immunity. By measuring IgG concentration in colostrum within 10 minutes, the product helps farmers and veterinarians select high-quality immune-rich colostrum. This rapid assessment can potentially increase survival rates and reduce disease incidence in calves and foals.

The WVC conference, expected to attract over 20,000 visitors and 600 companies, provides PROTIA with a strategic platform to demonstrate its technological capabilities and expand its global veterinary market presence. The event represents an opportunity for international collaboration and knowledge exchange among veterinary professionals.

PROTIA's CEO, Lim Kook-Jin, emphasized the company's commitment to developing innovative diagnostic technologies that support animal health management across companion and large animal sectors. The company's participation in WVC underscores its ambition to introduce advanced diagnostic solutions to the global veterinary market.